Table 1 Clinicopathological parameters, methylation and genetic alterations and its relation to cluster status
From: DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
All Samples (n = 115) | Cluster A (n = 81) | Cluster B (n = 34) | p-value | |
|---|---|---|---|---|
Age (median ± SD) | 65.0 ± 11.6 | 67.0 ± 11.5 | 63.0 ± 11.2 | 0.1031 |
Gender | ||||
Male | 66 | 42 | 24 | 0.0642 |
Female | 49 | 39 | 10 | |
Tumor diameter (mm, median ± SD) | 70.0 ± 41.6 | 55.0 ± 36.1 | 95.0 ± 38.5 | < 0.0011 |
Morphological grade | ||||
G1 | 16 | 16 | 0 | < 0.0012 |
G2 | 46 | 40 | 6 | |
G3 | 34 | 20 | 14 | |
G4 | 18 | 5 | 13 | |
T Stage | ||||
T1 | 50 | 47 | 3 | < 0.0012 |
T2 | 25 | 17 | 8 | |
T3 | 39 | 17 | 22 | |
T4 | 1 | 0 | 1 | |
M stage | ||||
M0 | 87 | 70 | 17 | < 0.0012 |
M1 | 28 | 11 | 17 | |
TNM | ||||
I | 49 | 46 | 3 | < 0.0012 |
II | 14 | 12 | 2 | |
III | 24 | 12 | 12 | |
IV | 28 | 11 | 17 | |
Progress (n = 87) | ||||
No | 64 | 57 | 7 | 0.0012 |
Yes | 23 | 13 | 10 | |
Follow Up Status | ||||
Living | 39 | 35 | 4 | < 0.0012 |
Living with disease | 5 | 3 | 2 | |
Dead in ccRCC | 45 | 20 | 25 | |
Dead | 26 | 23 | 3 | |
Average methylation (median ± SD) | 0.3215 ± 0.0136 | 0.3196 ± 0.0105 | 0.3344 ± 0.0127 | < 0.0011 |
Loss Chr 9p | ||||
WT | 73 | 62 | 11 | < 0.0012 |
Loss | 42 | 19 | 23 | |
Loss Chr 9q | ||||
WT | 75 | 62 | 13 | < 0.0012 |
Loss | 40 | 19 | 21 | |
Loss Chr 14q | ||||
WT | 76 | 60 | 16 | 0.0052 |
Loss | 39 | 21 | 18 | |
Risk score (n = 114) [33] | ||||
Low Risk | 63 | 45 | 18 | 0.7452 |
High Risk | 51 | 35 | 16 | |